BIOA at a glance
BioAge Labs, Inc. (BIOA, SEC CIK 1709941) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as July 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BioAge Labs, Inc. (BIOA) reported revenue of $9.0 million and a net loss of $80.6 million. Diluted EPS was -$2.24.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding BioAge Labs, Inc. (BIOA) shares worth $91.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Barton Shane on June 30, 2026 of 20,216 shares at $25.19 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $9.0M
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $91.6M · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Collaboration revenue $0.3M, down 85% YoY from $2.1M, reflecting a $1.7M Novartis catch-up adjustment
- Net loss $33.5M vs $20.2M YoY, with operating expenses $37.7M vs $25.2M
- BGE-102 R&D spending $17.8M vs $4.7M, the strongest program; other programs $4.4M vs $7.7M
- Cash, equivalents and marketable securities $352.3M; operating cash used $74.3M through nine months
- Funding expected through 2029; QUELL-CV topline data anticipated fourth quarter 2026, with additional capital needs and clinical risks remaining
Risk Factors
- Newly added regulatory risk: BIOSECURE Act, triggered by WuXi AppTec’s June 8, 2026 designation on the 1260H List
- Most material update: QUELL-DME began dosing approximately 180 participants, including combination therapy with anti-VEGF
- Near-term clinical risk: QUELL-CV topline data anticipated in fourth quarter of 2026, with hsCRP reduction potentially not translating into cardiovascular benefit
- Financial risk: $352.3 million in cash, equivalents and marketable securities expected to fund operations through 2029
- Manufacturing risk: China and India suppliers exposed to tariffs, trade restrictions and supply-chain disruption
AI summary of the BIOA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release attached as Exhibit 99.1, providing the substantive financial details
Item EX-99.1: Item EX-99.1
- QUELL-CV fully enrolled at approximately 160 participants, with 30 mg, 60 mg, and 90 mg doses; topline data expected Q4 2026
- QUELL-DME Phase 2 dosed its first participant, targeting approximately 180 patients; topline results expected in H2 2027
Item 8.01: Other Events
- First participant dosed in QUELL-DME, advancing BGE-102 into a randomized Phase 2 diabetic macular edema study
- Approximately 180 participants across three arms, testing BGE-102 monotherapy and combination use with anti-VEGF therapy
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss widened to $26.1M from $21.6M, while R&D rose to $24.4M as BGE-102 trials advanced
- QUELL-CV Phase 2 enrolled its first participant, testing 30 mg, 60 mg, and 90 mg doses in approximately 160 adults
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investor-relevant figures and management commentary contained in Exhibit 99.1 press release
AI summaries of BIOA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BIOA
Don't miss the next BIOA filing
- Alerts as it files. A push when BIOA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BIOA, by share count.
- Ask anything. An AI agent that reads every BIOA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Barton Shane | M | Jun 30, 2026 | 4,065 | - |
| Barton Shane | M | Jun 30, 2026 | 7,861 | - |
| Barton Shane | M | Jun 30, 2026 | 4,290 | - |
| Barton Shane | M | Jun 30, 2026 | 4,000 | - |
| Barton Shane | M | Jun 30, 2026 | 7,861 | $4.38 |
| Barton Shane | M | Jun 30, 2026 | 4,065 | $4.30 |
| Barton Shane | M | Jun 30, 2026 | 4,000 | $8.39 |
| Barton Shane | Sell | Jun 30, 2026 | 20,216 | $25.19 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $9.0M |
| Operating Income | -$48.4M | -$78.2M | -$92.8M |
| Net Income | - | -$71.1M | -$80.6M |
| Op. Margin | - | - | -1031.5% |
| Net Margin | - | - | -896.1% |
| Balance Sheet | |||
| Total Assets | $25.9M | $358.2M | $294.9M |
| Equity | -$173.4M | $323.1M | $272.1M |
| ROE | - | -22.0% | -29.6% |
| Per Share | |||
| EPS | - | $-6.63 | $-2.24 |
| Cash Flow | |||
| Operating CF | - | -$51.5M | -$81.6M |
| CapEx | $166K | $366K | $719K |
Source: XBRL data in BioAge Labs, Inc. (BIOA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BIOA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $91.6M |
| Q2 2026 | 27 | $239.8M |
| Q1 2026 | 25 | $140.5M |
| Q4 2025 | 23 | $74.5M |
| Q3 2025 | 21 | $28.1M |
| Q2 2025 | 20 | $16.7M |
| Q1 2025 | 12 | $4.1M |
| Q4 2024 | 8 | $3.1M |
- BlackRock+693.6K (+24%)
- JPMorgan Chase & Co+548.5K (+234%)
- Renaissance Technologies LLC+461.0K (+278%)
- Millennium Management+413.9K (+186%)
- D.E. Shaw & Co+413.6K (+56%)
- Bank of America Corp−180.2K (-70%)
- Invesco Ltd−82.7K (-65%)
- Citadel Advisors LLC−36.8K (-47%)
- Wells Fargo & Co−23.1K (-78%)
- Northern Trust−11.9K (-3%)
- FMR LLC (Fidelity)−183.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 162 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BIOA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 2, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | May 8, 2026 | - | Analysis | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 3, 2026 | - | - | - |
| 10-K | Mar 24, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 24, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 19, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BIOA SEC filings: frequently asked questions
Which institutions hold BIOA stock?
As of September 30, 2026, the largest BioAge Labs, Inc. (BIOA) holders among the 13F filers tracked by SignalX were BlackRock ($25.1 million), Vanguard Capital Management LLC ($11.5 million), State Street Corp ($9.6 million), D.E. Shaw & Co ($8.2 million), JPMorgan Chase & Co ($5.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BIOA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BioAge Labs, Inc. (BIOA) reported revenue of $9.0 million and a net loss of $80.6 million. Diluted EPS was -$2.24. The figures come from the XBRL data in the 10-K.
What did BIOA report in its latest 8-K?
BioAge Labs, Inc. (BIOA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest BIOA SEC filings?
BioAge Labs, Inc. (BIOA) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on July 1, 2026.
What is BIOA's SEC CIK number?
BioAge Labs, Inc. (BIOA)'s SEC Central Index Key (CIK) is 1709941. EDGAR lists every BIOA filing under that number.
Ask anything about BIOA
The research agent reads BIOA's filings, financials, insider trades and 13F holders, then answers with sources.